ArticleCurrent colorectal cancer reports2012
Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?
Article in Current colorectal cancer reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Progression of Femoral Osteolytic Metastases after Intramedullary Nailing and Subsequent Salvage Techniques.Cancers · 2024Article
- Systemic chemotherapy combined with radiofrequency ablation for colorectal cancer with liver metastasis: a retrospective cohort study.Annals of medicine and surgery (2012) · 2023Article
- Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis.International journal of hepatology · 2020Article
- Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave?World journal of radiology · 2017Article
- Radiofrequency Ablation to Improve Survival After Conversion Chemotherapy for Colorectal Liver Metastases.World journal of surgery · 2016Article
- Thermal ablation in colorectal liver metastases: Lack of evidence or lack of capability to prove the evidence?World journal of gastroenterology · 2016Article
- Impact of Systemic Therapy and Recurrence Pattern on Survival Outcome after Radiofrequency Ablation for Colorectal Liver Metastases.Journal of Cancer · 2016Article
- Cavitation-enhanced MR-guided focused ultrasound ablation of rabbit tumors in vivo using phase shift nanoemulsions.Physics in medicine and biology · 2014Article
- Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2013Article
- The role of interventional oncology in the treatment of colorectal cancer liver metastases.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with unresectable colorectal liver metastases (CRLM), radiofrequency ablation (RFA) might be a good alternative, whenever possible. In contrast to systemic therapy, the aim of RFA is to achieve complete local tumor control in an attempt to provide long-term survival. In this article we discuss the available evidence regarding the treatment of patients with unresectable CRLM, focusing on RFA in conjunction with modern systemic therapies. We observed that the available evidence in the existing literature is limited, and often consists of level 2 and 3 evidence, thereby hampering any firm conclusions. Nonetheless, RFA seems superior to chemotherapy alone in patients with liver-only disease amenable for RFA. However, the combination of RFA and chemotherapy has been demonstrated to be feasible and safe, lending support to the concept of RFA followed by chemotherapy, in order to reduce local recurrence rates and prolong survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.